AMN Healthcare Services (AMN)
(Delayed Data from NYSE)
$41.01 USD
-1.41 (-3.32%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $40.94 -0.07 (-0.17%) 7:58 PM ET
4-Sell of 5 4
A Value C Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$41.01 USD
-1.41 (-3.32%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $40.94 -0.07 (-0.17%) 7:58 PM ET
4-Sell of 5 4
A Value C Growth F Momentum B VGM
Zacks News
3 Reasons to Retain Ecolab (ECL) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Ecolab (ECL) owing to its solid product portfolio.
Zacks.com featured highlights include AMN Healthcare Services, Encore Wire and Global Ship
by Zacks Equity Research
AMN Healthcare Services, Encore Wire and Global Ship are part of Zacks Screen of the Week article.
Accuray (ARAY) Q4 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Despite solid Product revenues, Accuray (ARAY) reports an overall soft Q4 performance.
Alcon (ALC) Q2 Earnings Surpass Estimates, Guidance Lowered
by Zacks Equity Research
Alcon's (ALC) robust innovation pipeline is delivering solid results as evidenced by the successful launch of new ATIOL roles and SiHy contact lenses.
Zacks.com featured highlights include AMN Healthcare Services, Quanex Building Products, Sonoco and Super Micro Computer
by Zacks Equity Research
AMN Healthcare Services, Quanex Building Products, Sonoco and Super Micro Computer are part of Screen of the Week article.
3 Profitable Stocks to Buy on the Basis of Net Income Ratio
by Tirthankar Chakraborty
AMN Healthcare Services (AMN), Encore Wire (WIRE) and Global Ship Lease (GSL) have been selected as the top picks with a high net income ratio.
Wall Street Analysts Think AMN Healthcare (AMN) Could Surge 25%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for AMN Healthcare (AMN) points to a 25.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Masimo's (MASI) Q2 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Masimo's (MASI) robust product shipments and strength in its healthcare business drive its Q2 sales.
Avanos (AVNS) Q2 Earnings Top Estimates, FY22 View Lowered
by Zacks Equity Research
Avanos's (AVNS) second-quarter 2022 results reflect strength in the Pain Management segment.
4 Stocks Trading Near 52-Week High That Can Scale Higher
by Vasundhara Sawalka
Investors target stocks that have been on a bullish run lately. Stocks like AMN, NX, SON and SMCI that are seeing price strength have a high chance of carrying the momentum forward.
Best Momentum Stocks to Buy for August 9th
by Zacks Equity Research
AMN, BUSE and DNOW made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 9, 2022.
OPKO Health (OPK) Stock Gains 2.1% Despite Q2 Earnings Miss
by Zacks Equity Research
OPKO Health's (OPK) second-quarter results benefit from continued strength in its Pharmaceuticals segment.
Best Value Stocks to Buy for August 9th
by Zacks Equity Research
AMN, DOOO and NSIT made it to the Zacks Rank #1 (Strong Buy) value stocks list on August 9, 2022.
AMN vs. PGNY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
AMN vs. PGNY: Which Stock Is the Better Value Option?
Are Investors Undervaluing AMN Healthcare Services (AMN) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Inogen (INGN) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Inogen's (INGN) second-quarter results benefit from higher revenues in its international business-to-business sales channel.
Allscripts (MDRX) Q2 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Allscripts' (MDRX) robust Q2 results demonstrate strength in both segments.
AMN Healthcare (AMN) Q2 Earnings, Revenues Beat Estimates
by Zacks Equity Research
AMN Healthcare's (AMN) robust Q2 results demonstrate its segmental strength.
AMN Healthcare Services (AMN) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
AMN Healthcare (AMN) delivered earnings and revenue surprises of 11.82% and 4.76%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Medical Device Stocks Earnings on Aug 4: BDX, ABMD, AMN & DOCS
by Debanjana Dey
The Medical Device companies' Q2 results are likely to reflect strength in customer demand. Let's see how BDX, ABMD, AMN and DOCS are placed ahead of their earnings releases.
AMN Healthcare (AMN) to Post Q2 Earnings: What's in the Cards?
by Zacks Equity Research
AMN Healthcare's (AMN) second-quarter results are likely to reflect solid demand across all its segments.
AMN Healthcare Services (AMN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
AMN Healthcare Services (AMN) closed the most recent trading day at $113.34, moving +0.27% from the previous trading session.
Here's Why You Should Hold on to OPKO Health (OPK) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in Rayaldee and a few strategic agreements.
Here's Why You Should Hold On to DexCom (DXCM) Stock Now
by Zacks Equity Research
DexCom (DXCM) continues to benefit from a solid product portfolio and a strong international presence. However, supply constraints remain a woe.
Potbelly's and Rio Tinto have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Potbelly's and Rio Tinto have been highlighted as Zacks Bull and Bear of the Day.